New medical communications agency BoldScience launches
BoldScience, a new global medical communications agency, has launched.
The ‘scientifically creative’ agency is developing a unique blend of high science, creativity and innovation within a people-focussed culture.
Co-founders Mark Lydiatt, Mark Hardy, Yasmin Grant and Alison Lovibond have joined forces to launch BoldScience and its holding company, CO-LAB Global in both the US and UK.
Mark Lydiatt, CEO, BoldScience: “At BoldScience and CO-LAB Global, our goal is to help our pharmaceutical and biotech client partners to deliver the best, most impactful healthcare communications that help drive changes in treatment practises and ultimately improve patients’ lives.”
The co-founders were all previously senior leaders at Nucleus Global, with Lydiatt being the former Chief Executive Officer. The co-founding quad bring with them decades of experience across the breadth of strategic medical communications, creative design and digital service innovation.
Alison Lovibond, Chief Scientific Officer, BoldScience: “We were driven by a desire to build a people-focused agency that reflects our own vision of delivering the very best, forward-thinking med comms, within a positive workplace environment where individuals can thrive”.
Among the services on offer are communications strategy, medical affairs support, medical publications, scientific events, training, commercial support, expert engagement, and clinical trial support, with an industry-leading creative and digital offering underpinning all service areas.
Mark Hardy, Chief Creative Officer, BoldScience: “Too many agencies are either known for being scientific or being creative. With our integrated offering and hand-picked, in-house talent, we are delivering both high-science and top-end creative”.
Simultaneous opening of the CO-LAB Global holding company reflects the co-founders’ bold ambitions to create multiple agencies under the umbrella brand and become a major player in med comms. Despite the challenging global environment, BoldScience has been able to make strong inroads into their plan.
They have been helping global pharma and biotech clients develop and deliver virtual programming and remote expert engagement strategies, and are exploring collaborations with proprietary big data, digital and clinical research organizations. Ultimately, they plan to offer an extended suite of offerings beyond the full-service agency capabilities.
Yasmin Grant, Chief Commercial Officer, BoldScience:“We’ve been astounded at how quickly we’ve established ourselves. We believe that if we are true to our values and surround ourselves with people who love what they do and who strive to be the best, we can build great things together.”
The agency has teams established in Atlanta and Princeton, and an office in central London. Other locations will be considered globally in support of their growing client needs.
